Obesity, hypertension, insulin resistance, and dyslipidemia are all clusters of an entity called
“Metabolic Syndrome”. The global trends of this syndrome's incidence/prevalence continue …

Direct oral anticoagulants (DOACs) have catalyzed a significant paradigm shift in the
landscape of anticoagulant therapy, emerging as pivotal agents for the prevention of stroke …

A proportion of acute ischemic stroke (AIS) patients suffer from early neurological
deterioration (END) within 24 hours following intravenous thrombolysis (IVT), which greatly …

Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …

A major advancement in the field of medicine has been the introduction and usage of direct
oral anticoagulants (DOACs) such as dabigatran (Pradaxa), apixaban (Eliquis), and …

Abstract Background and Aim Obesity affects nearly 650 million adults worldwide, and the
prevalence is steadily rising. This condition has significant adverse effects on cardiovascular …

Obesity remains a US national health crisis and a growing concern worldwide.
Concerningly, individuals who are obese are at an increased risk for comorbid diseases that …

Abstract Background The 2021 International Society on Thrombosis and
Haemostasis'(ISTH) recommends standard doses of apixaban and rivaroxaban regardless …

Methods: Publications from Pubmed and Scopus databases assessing the effect of
advanced age, altered renal function, sarcopenia, obesity, medication adherence, and drug …